These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 7540404

  • 1. Renal cell carcinoma and interleukin-2: a review.
    Wagstaff J, Baars JW, Wolbink GJ, Hoekman K, Eerenberg-Belmer AJ, Hack CE.
    Eur J Cancer; 1995; 31A(3):401-8. PubMed ID: 7540404
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.
    Hermann GG.
    APMIS Suppl; 1993; 35():1-26. PubMed ID: 8251200
    [No Abstract] [Full Text] [Related]

  • 4. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
    Thompson JA, Benyunes MC, Bianco JA, Fefer A.
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):46-51. PubMed ID: 8284692
    [No Abstract] [Full Text] [Related]

  • 5. Interferons and interleukins in metastatic renal cell carcinoma.
    Choudhury M, Efros M, Mittelman A.
    Urology; 1993 Jan; 41(1 Suppl):67-72. PubMed ID: 7678365
    [Abstract] [Full Text] [Related]

  • 6. The management of renal cell carcinoma.
    Pittman K, Selby P.
    Crit Rev Oncol Hematol; 1994 Jun; 16(3):181-200. PubMed ID: 7521169
    [No Abstract] [Full Text] [Related]

  • 7. High-dose interleukin-2 in the therapy of metastatic renal-cell carcinoma.
    Parkinson DR, Sznol M.
    Semin Oncol; 1995 Feb; 22(1):61-6. PubMed ID: 7855620
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Renal cell cancer: is immunotherapy dead?
    Wagstaff J.
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix94-7. PubMed ID: 17631604
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Biologic response modifiers in the therapy of metastatic renal cell carcinoma.
    Quesada JR.
    Semin Oncol; 1988 Aug; 15(4):396-407. PubMed ID: 2457256
    [No Abstract] [Full Text] [Related]

  • 14. IL-2: efficacy in renal cell carcinoma and overall safety profile.
    Louie A.
    Cancer Invest; 1990 Aug; 8(2):315-6. PubMed ID: 2400958
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma.
    Pierce WC, Belldegrun A, Figlin RA.
    Semin Oncol; 1995 Feb; 22(1):74-80. PubMed ID: 7855622
    [No Abstract] [Full Text] [Related]

  • 17. Anti-tumor effects of interleukin 2 against renal cell carcinoma. In vitro study and clinical application.
    Marumo K, Tazaki H.
    Prog Clin Biol Res; 1990 Feb; 350():263-73. PubMed ID: 2117286
    [No Abstract] [Full Text] [Related]

  • 18. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.
    Fisher RI, Coltman CA, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, Wiernik P, McMannis JD, Weiss GR, Margolin KA.
    Ann Intern Med; 1988 Apr; 108(4):518-23. PubMed ID: 3258138
    [Abstract] [Full Text] [Related]

  • 19. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
    Figlin RA, Pierce WC, Belldegrun A.
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
    [No Abstract] [Full Text] [Related]

  • 20. IL-2 therapy proves durable in renal cell melanoma patients.
    Oncology (Williston Park); 1991 Sep; 5(9):71. PubMed ID: 1835879
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.